IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against hepatitis C virus genotype 1 or 4 in Caucasians

Objectives: The rs12979860 variant, linked to IL28B gene, predicts sustained viral response (SVR) to pegylated-interferon/ribavirin (pegIFN/RBV) therapy in Hepatitis C Virus genotype 1 or 4 (HCV-1/4)-infected patients. Recently, a functional variant, ss469415590, in linkage disequilibrium (LD) with...

ver descrição completa

Detalhes bibliográficos
Autores: Real, Luis M.|||0000-0003-4932-7429, Neukam, Karin, Herrero del Rio, Mª del Rocío|||0000-0002-9678-0309, Guardiola, Josep M., Reiberger, Thomas|||0000-0002-4590-3583, Rivero-Juarez, Antonio|||0000-0002-5813-6889, Salazar, Juliana|||0000-0002-3581-4499, Mandorfer, Mattias|||0000-0003-2330-0017, Merino, Dolores, Soriano, Vicente|||0000-0002-4624-5199, Rivero Román, Antonio|||0000-0002-8643-4250, Macías, Juan|||0000-0002-4778-790X, Pineda, Juan A.|||0000-0002-3751-0296, Caruz, Antonio
Formato: artículo
Fecha de publicación:2014
País:España
Recursos:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:302464
Acesso em linha:https://ddd.uab.cat/record/302464
https://dx.doi.org/urn:doi:10.1371/journal.pone.0095515
Access Level:acceso abierto
Palavra-chave:Adult
Alleles
Antiviral Agents
Coinfection
European Continental Ancestry Group
Female
Follow-Up Studies
Genotype
Hepacivirus
Hepatitis C, Chronic
Humans
Interleukins
Male
Middle Aged
Polymorphism, Single Nucleotide
ROC Curve
Treatment Outcome
id ES_7c287d7cfa76d90c72138b7bf0dd109c
oai_identifier_str oai:ddd.uab.cat:302464
network_acronym_str ES
network_name_str España
repository_id_str
spelling IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against hepatitis C virus genotype 1 or 4 in CaucasiansReal, Luis M.|||0000-0003-4932-7429Neukam, KarinHerrero del Rio, Mª del Rocío|||0000-0002-9678-0309Guardiola, Josep M.Reiberger, Thomas|||0000-0002-4590-3583Rivero-Juarez, Antonio|||0000-0002-5813-6889Salazar, Juliana|||0000-0002-3581-4499Mandorfer, Mattias|||0000-0003-2330-0017Merino, DoloresSoriano, Vicente|||0000-0002-4624-5199Rivero Román, Antonio|||0000-0002-8643-4250Macías, Juan|||0000-0002-4778-790XPineda, Juan A.|||0000-0002-3751-0296Caruz, AntonioAdultAllelesAntiviral AgentsCoinfectionEuropean Continental Ancestry GroupFemaleFollow-Up StudiesGenotypeHepacivirusHepatitis C, ChronicHumansInterleukinsMaleMiddle AgedPolymorphism, Single NucleotideROC CurveTreatment OutcomeObjectives: The rs12979860 variant, linked to IL28B gene, predicts sustained viral response (SVR) to pegylated-interferon/ribavirin (pegIFN/RBV) therapy in Hepatitis C Virus genotype 1 or 4 (HCV-1/4)-infected patients. Recently, a functional variant, ss469415590, in linkage disequilibrium (LD) with rs12979860, has been discovered. Our objective was to assess the value of ss469415590 to predict SVR to pegIFN/RBV in Caucasian HCV-1/4-infected individuals and to compare its performance with that of rs12979860. Methods: 272 Caucasian HCV-1/4-infected patients who completed a course of pegIFN/RBV were genotyped for both rs12979860 and ss469415590 markers. Logistic regression models including factors with univariate association with SVR and each genetic marker were elaborated. The area under the receiver operating-characteristic curve (AUROC) was calculated for each model and both were compared. Results: Both markers were in LD (r = 0.82). For rs12979860, 66 (64.0%) CC versus 56 (33.1%) T allele carriers achieved SVR (Adjusted OR = 4.156, 95%CI = 2.388-7.232, p = 4.647×10). For ss469415590, 66 (66.0%) TT/TT versus 56 (32.5%) -G allele carriers (Adjusted OR = 4.783, 95% CI = 2.714-8.428, p = 6.153×10) achieved SVR. The AUROC of the model including rs12979860 was 0.742 (95%CI = 0.672-0.813) and of that based on ss469415590 was 0.756 (95%CI = 0.687-0.826) (p = 0.780). Conclusions: The ss469415590 variant shows an equivalent performance to predict SVR to pegIFN/RBV than the rs2979860 in Caucasian HCV-1/4-infected patients. © 2014 Real et al.Universitat Autònoma de Barcelona 22014-01-0120142014-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/302464https://dx.doi.org/urn:doi:10.1371/journal.pone.0095515reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengMinisterio de Economía y Competitividad https://doi.org/10.13039/501100003329 RD12/0017open accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:3024642026-06-06T12:50:31Z
dc.title.none.fl_str_mv IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against hepatitis C virus genotype 1 or 4 in Caucasians
title IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against hepatitis C virus genotype 1 or 4 in Caucasians
spellingShingle IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against hepatitis C virus genotype 1 or 4 in Caucasians
Real, Luis M.|||0000-0003-4932-7429
Adult
Alleles
Antiviral Agents
Coinfection
European Continental Ancestry Group
Female
Follow-Up Studies
Genotype
Hepacivirus
Hepatitis C, Chronic
Humans
Interleukins
Male
Middle Aged
Polymorphism, Single Nucleotide
ROC Curve
Treatment Outcome
title_short IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against hepatitis C virus genotype 1 or 4 in Caucasians
title_full IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against hepatitis C virus genotype 1 or 4 in Caucasians
title_fullStr IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against hepatitis C virus genotype 1 or 4 in Caucasians
title_full_unstemmed IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against hepatitis C virus genotype 1 or 4 in Caucasians
title_sort IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against hepatitis C virus genotype 1 or 4 in Caucasians
dc.creator.none.fl_str_mv Real, Luis M.|||0000-0003-4932-7429
Neukam, Karin
Herrero del Rio, Mª del Rocío|||0000-0002-9678-0309
Guardiola, Josep M.
Reiberger, Thomas|||0000-0002-4590-3583
Rivero-Juarez, Antonio|||0000-0002-5813-6889
Salazar, Juliana|||0000-0002-3581-4499
Mandorfer, Mattias|||0000-0003-2330-0017
Merino, Dolores
Soriano, Vicente|||0000-0002-4624-5199
Rivero Román, Antonio|||0000-0002-8643-4250
Macías, Juan|||0000-0002-4778-790X
Pineda, Juan A.|||0000-0002-3751-0296
Caruz, Antonio
author Real, Luis M.|||0000-0003-4932-7429
author_facet Real, Luis M.|||0000-0003-4932-7429
Neukam, Karin
Herrero del Rio, Mª del Rocío|||0000-0002-9678-0309
Guardiola, Josep M.
Reiberger, Thomas|||0000-0002-4590-3583
Rivero-Juarez, Antonio|||0000-0002-5813-6889
Salazar, Juliana|||0000-0002-3581-4499
Mandorfer, Mattias|||0000-0003-2330-0017
Merino, Dolores
Soriano, Vicente|||0000-0002-4624-5199
Rivero Román, Antonio|||0000-0002-8643-4250
Macías, Juan|||0000-0002-4778-790X
Pineda, Juan A.|||0000-0002-3751-0296
Caruz, Antonio
author_role author
author2 Neukam, Karin
Herrero del Rio, Mª del Rocío|||0000-0002-9678-0309
Guardiola, Josep M.
Reiberger, Thomas|||0000-0002-4590-3583
Rivero-Juarez, Antonio|||0000-0002-5813-6889
Salazar, Juliana|||0000-0002-3581-4499
Mandorfer, Mattias|||0000-0003-2330-0017
Merino, Dolores
Soriano, Vicente|||0000-0002-4624-5199
Rivero Román, Antonio|||0000-0002-8643-4250
Macías, Juan|||0000-0002-4778-790X
Pineda, Juan A.|||0000-0002-3751-0296
Caruz, Antonio
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universitat Autònoma de Barcelona
dc.subject.none.fl_str_mv Adult
Alleles
Antiviral Agents
Coinfection
European Continental Ancestry Group
Female
Follow-Up Studies
Genotype
Hepacivirus
Hepatitis C, Chronic
Humans
Interleukins
Male
Middle Aged
Polymorphism, Single Nucleotide
ROC Curve
Treatment Outcome
topic Adult
Alleles
Antiviral Agents
Coinfection
European Continental Ancestry Group
Female
Follow-Up Studies
Genotype
Hepacivirus
Hepatitis C, Chronic
Humans
Interleukins
Male
Middle Aged
Polymorphism, Single Nucleotide
ROC Curve
Treatment Outcome
description Objectives: The rs12979860 variant, linked to IL28B gene, predicts sustained viral response (SVR) to pegylated-interferon/ribavirin (pegIFN/RBV) therapy in Hepatitis C Virus genotype 1 or 4 (HCV-1/4)-infected patients. Recently, a functional variant, ss469415590, in linkage disequilibrium (LD) with rs12979860, has been discovered. Our objective was to assess the value of ss469415590 to predict SVR to pegIFN/RBV in Caucasian HCV-1/4-infected individuals and to compare its performance with that of rs12979860. Methods: 272 Caucasian HCV-1/4-infected patients who completed a course of pegIFN/RBV were genotyped for both rs12979860 and ss469415590 markers. Logistic regression models including factors with univariate association with SVR and each genetic marker were elaborated. The area under the receiver operating-characteristic curve (AUROC) was calculated for each model and both were compared. Results: Both markers were in LD (r = 0.82). For rs12979860, 66 (64.0%) CC versus 56 (33.1%) T allele carriers achieved SVR (Adjusted OR = 4.156, 95%CI = 2.388-7.232, p = 4.647×10). For ss469415590, 66 (66.0%) TT/TT versus 56 (32.5%) -G allele carriers (Adjusted OR = 4.783, 95% CI = 2.714-8.428, p = 6.153×10) achieved SVR. The AUROC of the model including rs12979860 was 0.742 (95%CI = 0.672-0.813) and of that based on ss469415590 was 0.756 (95%CI = 0.687-0.826) (p = 0.780). Conclusions: The ss469415590 variant shows an equivalent performance to predict SVR to pegIFN/RBV than the rs2979860 in Caucasian HCV-1/4-infected patients. © 2014 Real et al.
publishDate 2014
dc.date.none.fl_str_mv 2
2014-01-01
2014
2014-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/302464
https://dx.doi.org/urn:doi:10.1371/journal.pone.0095515
url https://ddd.uab.cat/record/302464
https://dx.doi.org/urn:doi:10.1371/journal.pone.0095515
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.relation.none.fl_str_mv Ministerio de Economía y Competitividad https://doi.org/10.13039/501100003329 RD12/0017
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869411569181392896
score 15.812429